Publications


clear
Download BibTeX

Tumor and microenvironment response but no cytotoxic T-cell activation in classic Hodgkin lymphoma treated with anti-PD1


Sarah Reinke, Paul J Bröckelmann, Ingram Iaccarino, Maria Alejandra Garcia-Marquez, Sven Borchmann, Franziska Jochims, Michaela Kotrova, Karol Pal, Monika Brüggemann, Elena Hartmann, others


Blood, 2020


Throly Score Successfully Classifies Hodgkin Lymphoma Patients at Risk of Thromboembolic Complication


Darko Antic, Vladimir Otasevic, Sven Borchmann, Horst Muller, Vojin Vukovic, Vladislava Djurasinovic, Kristina Tomic, Biljana Mihaljevic, Grigoris Gerotziafas, Andreas Engert, Jawed Fareed


Blood, 2020 Oct 5, pp. 8-8


Liquid biopsy in lymphoma: Molecular methods and clinical applications.


Melita Cirillo, Alexander F.M. Craig, Sven Borchmann*, David M. Kurtz*, *co-corresponding author


Cancer Treatment Reviews, 2020 Aug 22


Steering Chimeric Antigen Receptor T Cells Into the Hodgkin Lymphoma Niche.


Paul J. Bröckelmann, Sven Borchmann, Peter Borchmann, Andreas Engert


Journal of Clinical Oncology, 2020 Aug 18


Clearance of JC polyomavirus from cerebrospinal fluid following treatment with interleukin-2 and pembrolizumab in an individual with progressive multifocal leukoencephalopathy and no underlying immune deficiency syndrome.


Yasemin Goereci, Finja Schweitzer, Anton Wellstein, Steffi Silling, Sven Borchmann, Bastian von Tresckow, Ortwin Adams, Roland Martin, Mark Schlamann, Michael Schroeter, Gereon R. Fink, Mike P. Wattjes, Clemens Warnke


European Journal of Neurology, 2020 Jun 9


Inhibition of Tumor VEGFR2 Induces Serine 897 EphA2-Dependent Tumor Cell Invasion and Metastasis in NSCLC.


Caroline Volz, Sara Breid, Carolin Selenz, Alina Zaplatina, Kristina Golfmann, Lydia Meder, Felix Dietlein, Sven Borchmann, Sampurna Chatterjee, Maike Siobal, Jakob Schöttle, Alexandra Florin, Mirjam Koker, Marieke Nill, Luka Ozretić, Niklas Uhlenbrock, Steven Smith, Reinhard Büttner, Hui Miao, Bingcheng Wang, H. Christian Reinhardt, Daniel Rauh, Michael Hallek, Amparo Acker-Palmer, Lukas C. Heukamp, Roland T. Ullrich


Cell Reports, vol. 31(4), 2020 Mar 28


An update on disease biomarkers for Hodgkin lymphoma.


Melita Cirillo, Sven Borchmann


Expert Review of Hematology, vol. 13(5), 2020 Mar 2, pp. 481-488


Programmed cell death protein1 (PD1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse after conventional chemotherapy and at relapse on anti-PD1 treatment


Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, Sven Borchmann, Ilske Oschlies, Antje Schnitter, Andreas Engert, Peter Borchmann, Wolfram Klapper


haematologica, Ferrata Storti Foundation, 2019, pp. e45


Pretreatment Vitamin D Deficiency Is Associated With Impaired Progression-Free and Overall Survival in Hodgkin Lymphoma


Sven Borchmann, Melita Cirillo, Helen Goergen, Lydia Meder, Stephanie Sasse, Stefanie Kreissl, Paul Jan Bröckelmann, Bastian von Tresckow, Michael Fuchs, Roland Tillmann Ullrich, Andreas Engert


Journal of Clinical Oncology, vol. 37(36), 2019 Sep 17, pp. 3528-3537


Nivolumab in Relapsed/Refractory Classical Hodgkin Lymphoma - Extended Follow-up of 30 Patients Treated Within the CheckMate 205 Trial in a Single-Center.


Jesko Momotow, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Sven Borchmann, Bastian v. Tresckow, Carsten Kobe, Andreas Engert, Stephanie Sasse


HemaSphere, vol. 3(5), 2019 Aug 27


Thrombosis as a treatment complication in Hodgkin lymphoma patients: a comprehensive analysis of three prospective randomized German Hodgkin Study Group (GHSG) trials.


S. Borchmann, H. Müller, I. Hude, M. Fuchs, P. Borchmann, A. Engert


Annals of Oncology, vol. 30(8), 2019 Jul 1, pp. 1329-1334


The Khorana score for prediction of venous thromboembolism in cancer patients: a systematic review and meta-analysis.


Frits I. Mulder, Matteo Candeloro, Pieter W. Kamphuisen, Marcello Di Nisio, Patrick M. Bossuyt, Noori Guman, Kirsten Smit, Harry R. Büller, Nick van Es


Haematologica, vol. 104(6), 2019 May 1, pp. 1277-1287


Active surveillance for nodular lymphocyte-predominant Hodgkin lymphoma


Sven Borchmann, Erel Joffe, Craig H. Moskowitz, Andrew D. Zelenetz, Ariela Noy, Carol S. Portlock, John F. Gerecitano, Connie L. Batlevi, Philip C. Caron, Pamela Drullinsky, Audrey Hamilton, Paul A. Hamlin, Steven M. Horwitz, Anita Kumar, Matthew J. Matasar, Alison J. Moskowitz, Colette N. Owens, M. Lia Palomba, Anas Younes, David J. Straus


Blood, vol. 133(20), 2019 Apr 16, pp. 2121-2129


Suicide in European Hodgkin Lymphoma Patients.


Austin I. Kim, Helen Goergen, Andreas Engert, Ann S. LaCasce, Louise S. Maranda, Bruce A. Barton, Sven Borchmann


HemaSphere, vol. 3(2), 2019 Jan 21


Symptomatic osteonecrosis as a treatment complication in Hodgkin lymphoma: an analysis of the German Hodgkin Study Group (GHSG)


Sven Borchmann, Horst Müller, Heinz Haverkamp, Christian Baues, Jana Marková, Andreas Hüttmann, Axel Glunz, Michael Fuchs, Peter Borchmann, Andreas Engert


Leukemia, vol. 33(2), 2019 Jan 1, pp. 439-446


The translational science of hodgkin lymphoma


Melita Cirillo, Sarah Reinke, Wolfram Klapper, Sven Borchmann


British Journal of Haematology, vol. 184(1), 2019 1, pp. 30-44


Programmed cell death protein-1 (PD-1)-expression in the microenvironment of classical Hodgkin lymphoma at relapse during anti-PD-1-treatment.


Stephanie Sasse, Katharina Reddemann, Arjan Diepstra, Ilske Oschlies, Antje Schnitter, Sven Borchmann, Andreas Engert, Peter Borchmann, Wolfram Klapper


Haematologica, vol. 104(1), 2019 1


Examining rare side effects in pooled trial data: symptomatic osteonecrosis in Hodgkin lymphoma


Sven Borchmann, Andreas Engert


Oncotarget, Impact Journals, LLC, 2018, p. 37462


Hodgkin lymphoma in elderly patients


Sven Borchmann, Andreas Engert, Boris Böll


Current opinion in oncology, LWW, 2018, pp. 308--316


Combined VEGF and PD-L1 Blockade Displays Synergistic Treatment Effects in an Autochthonous Mouse Model of Small Cell Lung Cancer.


Lydia Meder, Philipp Schuldt, Martin Thelen, Anna Schmitt, Felix Dietlein, Sebastian Klein, Sven Borchmann, Kerstin Wennhold, Ignacija Vlasic, Sebastian Oberbeck, Richard Riedel, Alexandra Florin, Kristina Golfmann, Hans A. Schlößer, Margarete Odenthal, Reinhard Buettner, Juergen Wolf, Michael Hallek, Marco Herling, Michael von Bergwelt-Baildon, H. Christian Reinhardt, Roland T. Ullrich


Cancer Research, vol. 78(15), 2018 Jul 1, pp. 4270-4281


Synergistic anti-angiogenic treatment effects by dual FGFR1 and VEGFR1 inhibition in FGFR1-amplified breast cancer.


Kristina Golfmann, Lydia Meder, Mirjam Koker, Caroline Volz, Sven Borchmann, Lars Tharun, Felix Dietlein, Florian Malchers, Alexandra Florin, Reinhard Büttner, Neal Rosen, Vanessa Rodrik-Outmezguine, Michael Hallek, Roland T Ullrich


Oncogene, vol. 37(42), 2018 Jun 3, pp. 5682-5693


Leucocyte and eosinophil counts predict progression-free survival in relapsed or refractory classical Hodgkin Lymphoma patients treated with PD1 inhibition.


Ida Hude, Stephanie Sasse, Paul J. Bröckelmann, Bastian von Tresckow, Jesko Momotow, Andreas Engert, Sven Borchmann


British Journal of Haematology, vol. 181(6), 2018 May 1, pp. 837-840


The genetics of Hodgkin lymphoma: an overview and clinical implications


Sven Borchmann, Andreas Engert


Current Opinion in Oncology, Wolters Kluwer, 2017, pp. 307--314


Hodgkin Lymphoma has a seasonal pattern of incidence and mortality that depends on latitude


Sven Borchmann, Horst Müller, Andreas Engert


Scientific reports, Nature Publishing Group, 2017, pp. 1--8


Novel agents in classical Hodgkin lymphoma


Sven Borchmann, Bastian von Tresckow


Leukemia \& lymphoma, Taylor \& Francis, 2017, pp. 2275--2286


Long-Term Follow-Up of Contemporary Treatment in Early-Stage Hodgkin Lymphoma: Updated Analyses of the German Hodgkin Study Group HD7, HD8, HD10, and HD11 Trials


Stephanie Sasse, Paul J Bröckelmann, Helen Goergen, Annette Plütschow, Horst Müller, Stefanie Kreissl, Carolin Buerkle, Sven Borchmann, Michael Fuchs, Peter Borchmann, Volker Diehl, Andreas Engert


Journal of Clinical Oncology, vol. 35(18), 2017 Mar 18, pp. 1999-2007


Current developments in the treatment of early-stage classical Hodgkin lymphoma.


Sven Borchmann, Bastian von Tresckow, Andreas Engert


Current Opinion in Oncology, vol. 28(5), 2016 Aug 1, pp. 377-383


Bleomycin in older early-stage favorable Hodgkin lymphoma patients: analysis of the German Hodgkin Study Group (GHSG) HD10 and HD13 trials


Boris Böll, Helen Goergen, Karolin Behringer, Paul J. Bröckelmann, Felicitas Hitz, Andrea Kerkhoff, Richard Greil, Bastian von Tresckow, Dennis A. Eichenauer, Carolin Bürkle, Sven Borchmann, Michael Fuchs, Volker Diehl, Andreas Engert, Peter Borchmann


Blood, vol. 127(18), 2016 Apr 5, pp. 2189-2192


Multi-specific antibodies for cancer immunotherapy


Ron D* Jachimowicz, Sven* Borchmann, Achim Rothe, *contributed equally


BioDrugs, Springer International Publishing, 2014, pp. 331--343


The bispecific immunoligand ULBP2-aCEA redirects natural killer cells to tumor cells and reveals potent anti-tumor activity against colon carcinoma


Achim Rothe*, Ron D. Jachimowicz*, Sven Borchmann*, Marie Madlener, Jörg Keßler, Katrin S. Reiners, Maike Sauer, Hinrich P. Hansen, Roland T. Ullrich, Sampurna Chatterjee, Peter Borchmann, Paul Yazaki, Thomas C. Koslowsky, Andreas Engert, Lukas C. Heukamp, Michael Hallek, Elke Pogge Von Strandmann, *contributed equally


International Journal of Cancer, vol. 134(12), 2014 May 15, pp. 2829-2840